# A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

> **NCT02753127** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 1253 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Napabucasin
- **DRUG:** Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Irinotecan
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT02753127
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2020-04-28
- **Final completion:** 2021-05-12
- **Target enrollment:** 1253 (ACTUAL)
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02753127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02753127, "A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02753127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*